Table 2.
Description of the aggregated RCGP and hospitalised cohort person-years and herpes zoster events according to vaccine eligibility, year and age
| GP consultations (RCGP RSC) | Hospitalisations (England) | ||||||||||||
| Factor | Level | Eligible for vaccination | Not eligible for vaccination | Eligible for vaccination | Not eligible for vaccination | ||||||||
| Total person-years* (1000s) | Herpes zoster events (rate per 1000 person- years) | PHN events (rate per 1000 person-years) | Total person-years (1000s) | Herpes zoster events (rate per 1000 person- years) | PHN events (rate per 1000 person-years) | Total person-years* (1000s) | Herpes zoster events (rate per 10 000 person- years) | PHN events (rate per 10 000 person-years) | Total person-years (1000s) | Herpes zoster events (rate per 10 000 person- years) | PHN events (rate per 10 000 person-years) | ||
| Year |
2005–06 | 446 | 3514 (7.9) | 510 (1.1) | |||||||||
| 2006–07 | 463 | 3738 (8.1) | 548 (1.2) | ||||||||||
| 2007–08 | 485 | 3907 (8.1) | 562 (1.2) | ||||||||||
| 2008–09 | 501 | 4010 (8.0) | 573 (1.1) | 11 104 | 3658 (3.3) | 592 (0.5) | |||||||
| 2009–10 | 516 | 4187 (8.1) | 598 (1.2) | 11 285 | 3987 (3.5) | 739 (0.7) | |||||||
| 2010–11 | 529 | 4266 (8.1) | 595 (1.1) | 11 440 | 4042 (3.5) | 773 (0.7) | |||||||
| 2011–12 | 542 | 4386 (8.1) | 625 (1.2) | 11 593 | 4142 (3.6) | 821 (0.7) | |||||||
| 2012–13 | 556 | 4586 (8.3) | 652 (1.2) | 11 753 | 4280 (3.6) | 878 (0.7) | |||||||
| 2013–14 | 38 | 252 (6.6) | 39 (1.0) | 532 | 4357 (8.2) | 621 (1.2) | 816 | 227 (2.8) | 66 (0.8) | 11 118 | 4223 (3.8) | 950 (0.9) | |
| 2014–15 | 94 | 555 (5.9) | 77 (0.8) | 489 | 3946 (8.1) | 584 (1.2) | 1969 | 666 (3.4) | 182 (0.9) | 10 132 | 3919 (3.9) | 859 (0.8) | |
| 2015–16 | 133 | 828 (6.2) | 117 (0.9) | 462 | 3536 (7.7) | 511 (1.1) | 2777 | 949 (3.4) | 224 (0.8) | 9502 | 3688 (3.9) | 802 (0.8) | |
| 2016–17 | 173 | 1074 (6.2) | 140 (0.8) | 432 | 3410 (7.9) | 478 (1.1) | 3666 | 1417 (3.9) | 339 (0.9) | 8804 | 3514 (4.0) | 791 (0.9) | |
| 2017–18 | 219 | 1320 (6.0) | 211 (1.0) | 351 | 2688 (7.7) | 352 (1.0) | 4412 | 1904 (4.3) | 481 (1.1) | 7123 | 2830 (4.0) | 584 (0.8) | |
| Age |
60–69† | 3415 | 23 381 (6.8) | 2402 (0.7) | 57 270 | 9897 (1.7) | 1849 (0.3) | ||||||
| 70–73 | 346 | 1940 (5.6) | 234 (0.7) | 715 | 6154 (8.6) | 862 (1.2) | 7164 | 1874 (2.6) | 434 (0.6) | 10 951 | 3303 (3.0) | 755 (0.7) | |
| 74–77 | 26 | 139 (5.4) | 14 (0.5) | 843 | 7696 (9.1) | 1299 (1.5) | 519 | 153 (3.0) | 38 (0.7) | 14 016 | 6287 (4.5) | 1453 (1.0) | |
| 78–82 | 271 | 1850 (6.8) | 321 (1.2) | 608 | 5946 (9.8) | 1135 (1.9) | 5669 | 2925 (5.2) | 774 (1.4) | 9240 | 5888 (6.4) | 1352 (1.5) | |
| 83–89† | 14 | 100 (7.0) | 15 (1.1) | 722 | 7354 (10.2) | 1511 (2.1) | 288 | 211 (7.3) | 46 (1.6) | 12 378 | 12 908 (10.4) | 2380 (1.9) | |
*Vaccine eligible person-years includes all time from the point that each age-cohort vaccination first became eligible to receive vaccine.
†Age group not eligible for vaccination.
GP, general practice; PHN, postherpetic neuralgia; RCGP, Royal College of General Practitioners; RSC, Research and Surveillance Centre.